{"protocolSection": {"identificationModule": {"nctId": "NCT00449930", "orgStudyIdInfo": {"id": "0431-049"}, "secondaryIdInfos": [{"id": "MK0431-049"}, {"id": "2006_561"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)", "officialTitle": "A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Metformin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control"}, "statusModule": {"statusVerifiedDate": "2017-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-03-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2008-07-25", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-07-25", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-03-19", "studyFirstSubmitQcDate": "2007-03-19", "studyFirstPostDateStruct": {"date": "2007-03-21", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-06-23", "resultsFirstSubmitQcDate": "2009-06-23", "resultsFirstPostDateStruct": {"date": "2009-08-11", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-04-05", "lastUpdatePostDateStruct": {"date": "2017-05-11", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "A study to evaluate the efficacy and safety of sitagliptin in comparison to a commonly used medication in patients with type 2 diabetes"}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 1050, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "Drug", "interventionNames": ["Drug: sitagliptin phosphate"]}, {"label": "2", "type": "ACTIVE_COMPARATOR", "description": "Active comparator", "interventionNames": ["Drug: Comparator: metformin hydrochloride"]}], "interventions": [{"type": "DRUG", "name": "sitagliptin phosphate", "description": "(1) sitagliptin 100mg tablet once daily (q.d.) for a 24-wk treatment period", "armGroupLabels": ["1"], "otherNames": ["MK0431"]}, {"type": "DRUG", "name": "Comparator: metformin hydrochloride", "description": "(4) Metformin 500mg tablets once daily (q.d.) for a 24-wk treatment period.", "armGroupLabels": ["2"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24", "description": "HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent.", "timeFrame": "Baseline and 24 weeks"}], "secondaryOutcomes": [{"measure": "Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Diarrhea", "timeFrame": "Baseline to Week 24"}, {"measure": "Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Nausea", "timeFrame": "Baseline to Week 24"}, {"measure": "Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Abdominal Pain", "timeFrame": "Baseline to Week 24"}, {"measure": "Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Vomiting", "timeFrame": "Baseline to Week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "General Inclusion Criteria:\n\n* Patient has type 2 diabetes mellitus (T2DM)\n* Patient is inadequately controlled and not on treatment with insulin or oral antihyperglycemic therapy\n\nGeneral Exclusion Criteria:\n\n* Patient has a history of type 1 diabetes mellitus or history of ketoacidosis\n* Patient was on antihyperglycemic therapy (insulin or oral) within the prior 4 months", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "78 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "20070351", "type": "RESULT", "citation": "Aschner P, Katzeff HL, Guo H, Sunga S, Williams-Herman D, Kaufman KD, Goldstein BJ; Sitagliptin Study 049 Group. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab. 2010 Mar;12(3):252-61. doi: 10.1111/j.1463-1326.2009.01187.x. Epub 2009 Nov 25."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf\n\nhttp://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Patients 18-78 years of age with Type 2 diabetes mellitus (T2DM) who were not on anti-hyperglycemic agents for at least 4 months (16 weeks) and with a hemoglobin A1c (HbA1c) of \u2265 6.5 and \u22649.0%", "recruitmentDetails": "First patient In: 04-Apr-2007\n\nLast Patient Last Visit: 25-Jul-2008\n\n113 study centers worldwide", "groups": [{"id": "FG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablet of sitagliptin once daily."}, {"id": "FG001", "title": "Metformin", "description": "The Metformin group includes data from patients randomized to receive treatment with metformin initiated at a dose of 1 tablet (500 mg) per day. Patients were then to be up-titrated over a maximum of 5 weeks to a total daily dose of 2 tablets twice daily (1000 mg b.i.d)."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "528"}, {"groupId": "FG001", "numSubjects": "522"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "467"}, {"groupId": "FG001", "numSubjects": "447"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "61"}, {"groupId": "FG001", "numSubjects": "75"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "19"}]}, {"type": "Trial Terminated ( Site Closed)", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "15"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "23"}]}, {"type": "Glycemic discontinuation criteria", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablet of sitagliptin once daily."}, {"id": "BG001", "title": "Metformin", "description": "The Metformin group includes data from patients randomized to receive treatment with metformin initiated at a dose of 1 tablet (500 mg) per day. Patients were then to be up-titrated over a maximum of 5 weeks to a total daily dose of 2 tablets twice daily (1000 mg b.i.d)."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "528"}, {"groupId": "BG001", "value": "522"}, {"groupId": "BG002", "value": "1050"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.9", "spread": "10.7"}, {"groupId": "BG001", "value": "56.1", "spread": "10.4"}, {"groupId": "BG002", "value": "56.0", "spread": "10.6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "278"}, {"groupId": "BG001", "value": "288"}, {"groupId": "BG002", "value": "566"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "250"}, {"groupId": "BG001", "value": "234"}, {"groupId": "BG002", "value": "484"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "397"}, {"groupId": "BG001", "value": "395"}, {"groupId": "BG002", "value": "792"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "43"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "64"}, {"groupId": "BG001", "value": "62"}, {"groupId": "BG002", "value": "126"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "43"}, {"groupId": "BG001", "value": "46"}, {"groupId": "BG002", "value": "89"}]}]}]}, {"title": "Body Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Kilograms", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "84.9", "spread": "17.7"}, {"groupId": "BG001", "value": "84.6", "spread": "17.2"}, {"groupId": "BG002", "value": "84.7", "spread": "17.5"}]}]}]}, {"title": "Hemoglobin A1c (HbA1c)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.2", "spread": "0.7"}, {"groupId": "BG001", "value": "7.3", "spread": "0.7"}, {"groupId": "BG002", "value": "7.3", "spread": "0.7"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24", "description": "HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent.", "populationDescription": "The per protocol population required that a patient had measurements both at baseline and at Week 24, and did not have any major protocol violations (e.g. drug compliance \\<85%, addition of prohibited antihyperglycemic agent, incorrect double-blind study medication). No missing data were imputed.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent", "timeFrame": "Baseline and 24 weeks", "groups": [{"id": "OG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablet of sitagliptin once daily."}, {"id": "OG001", "title": "Metformin", "description": "The Metformin group includes data from patients randomized to receive treatment with metformin initiated at a dose of 1 tablet (500 mg) per day. Patients were then to be up-titrated over a maximum of 5 weeks to a total daily dose of 2 tablets twice daily (1000 mg b.i.d)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "455"}, {"groupId": "OG001", "value": "439"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.43", "lowerLimit": "-0.48", "upperLimit": "-0.38"}, {"groupId": "OG001", "value": "-0.57", "lowerLimit": "-0.62", "upperLimit": "-0.51"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "The pre-specified non-inferiority margin was 0.4%; i.e., non-inferiority required that the upper boundary of the 95% confidence interval for the treatment difference (sitagliptin minus metformin) to be less than 0.4%.", "paramType": "Mean Difference (Net)", "paramValue": "0.14", "ciPctValue": "95", "ciLowerLimit": "0.06", "ciUpperLimit": "0.21", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "0.57", "estimateComment": "Based on an analysis of covariance (ANCOVA) model with terms for treatment group and baseline value."}]}, {"type": "SECONDARY", "title": "Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Diarrhea", "populationDescription": "All randomized patients who received at least 1 dose of the double-blind study therapy.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Baseline to Week 24", "groups": [{"id": "OG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablet of sitagliptin once daily."}, {"id": "OG001", "title": "Metformin", "description": "The Metformin group includes data from patients randomized to receive treatment with metformin initiated at a dose of 1 tablet (500 mg) per day. Patients were then to be up-titrated over a maximum of 5 weeks to a total daily dose of 2 tablets twice daily (1000 mg b.i.d)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "528"}, {"groupId": "OG001", "value": "522"}]}], "classes": [{"title": "Patients Who Reported Diarrhea", "categories": [{"measurements": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "57"}]}]}, {"title": "Patients Who Did Not Report Diarrhea", "categories": [{"measurements": [{"groupId": "OG000", "value": "509"}, {"groupId": "OG001", "value": "465"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Fisher Exact", "paramType": "Risk Difference (RD)", "paramValue": "-7.3", "ciPctValue": "95", "ciLowerLimit": "-10.6", "ciUpperLimit": "-4.2", "estimateComment": "Difference (sitagliptin minus metformin) in the percentage of patients with diarrhea.\n\nWilson Score method was used for the 95% Confidence Interval (CI)."}]}, {"type": "SECONDARY", "title": "Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Nausea", "populationDescription": "All randomized patients who received at least 1 dose of the double-blind study therapy.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Baseline to Week 24", "groups": [{"id": "OG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablet of sitagliptin once daily."}, {"id": "OG001", "title": "Metformin", "description": "The Metformin group includes data from patients randomized to receive treatment with metformin initiated at a dose of 1 tablet (500 mg) per day. Patients were then to be up-titrated over a maximum of 5 weeks to a total daily dose of 2 tablets twice daily (1000 mg b.i.d)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "528"}, {"groupId": "OG001", "value": "522"}]}], "classes": [{"title": "Patients Who Reported Nausea", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "16"}]}]}, {"title": "Patients Who Did Not Report Nausea", "categories": [{"measurements": [{"groupId": "OG000", "value": "522"}, {"groupId": "OG001", "value": "506"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.032", "statisticalMethod": "Fisher Exact", "paramType": "Risk Difference (RD)", "paramValue": "-1.9", "ciPctValue": "95", "ciLowerLimit": "-3.9", "ciUpperLimit": "-0.2", "estimateComment": "Difference (sitagliptin minus metformin) in the percentage of patients with nausea.\n\nWilson Score method was used for the 95% CI."}]}, {"type": "SECONDARY", "title": "Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Abdominal Pain", "populationDescription": "All randomized patients who received at least 1 dose of the double-blind study therapy.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Baseline to Week 24", "groups": [{"id": "OG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablet of sitagliptin once daily."}, {"id": "OG001", "title": "Metformin", "description": "The Metformin group includes data from patients randomized to receive treatment with metformin initiated at a dose of 1 tablet (500 mg) per day. Patients were then to be up-titrated over a maximum of 5 weeks to a total daily dose of 2 tablets twice daily (1000 mg b.i.d)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "528"}, {"groupId": "OG001", "value": "522"}]}], "classes": [{"title": "Patients Who Reported Abdominal Pain", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "20"}]}]}, {"title": "Patients Who Did Not Report Abdominal Pain", "categories": [{"measurements": [{"groupId": "OG000", "value": "517"}, {"groupId": "OG001", "value": "502"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.103", "statisticalMethod": "Fisher Exact", "paramType": "Risk Difference (RD)", "paramValue": "-1.7", "ciPctValue": "95", "ciLowerLimit": "-4.0", "ciUpperLimit": "0.3", "estimateComment": "Difference (sitagliptin minus metformin) in the percentage of patients with abdominal pain.\n\nWilson Score method was used for the 95% CI."}]}, {"type": "SECONDARY", "title": "Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Vomiting", "populationDescription": "All randomized patients who received at least 1 dose of the double-blind study therapy.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Baseline to Week 24", "groups": [{"id": "OG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablet of sitagliptin once daily."}, {"id": "OG001", "title": "Metformin", "description": "The Metformin group includes data from patients randomized to receive treatment with metformin initiated at a dose of 1 tablet (500 mg) per day. Patients were then to be up-titrated over a maximum of 5 weeks to a total daily dose of 2 tablets twice daily (1000 mg b.i.d)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "528"}, {"groupId": "OG001", "value": "522"}]}], "classes": [{"title": "Patients Who Reported Vomiting", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "Patients Who Did Not Report Vomiting", "categories": [{"measurements": [{"groupId": "OG000", "value": "526"}, {"groupId": "OG001", "value": "515"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Risk Difference (RD)", "paramValue": "-1.0", "ciPctValue": "95", "ciLowerLimit": "-2.4", "ciUpperLimit": "0.2", "estimateComment": "Difference (sitagliptin minus metformin) in the percentage of patients with vomiting.\n\nWilson Score method was used for the 95% CI."}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablet of sitagliptin once daily.", "seriousNumAffected": 10, "otherNumAffected": 19}, {"id": "EG001", "title": "Metformin", "description": "The Metformin group includes data from patients randomized to receive treatment with metformin initiated at a dose of 1 tablet (500 mg) per day. Patients were then to be up-titrated over a maximum of 5 weeks to a total daily dose of 2 tablets twice daily (1000 mg b.i.d).", "seriousNumAffected": 8, "otherNumAffected": 57}], "seriousEvents": [{"term": "Any Cardiac disorders", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 522}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 522}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 522}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 522}]}, {"term": "Tachyarrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 522}]}, {"term": "Any Congenital, familial and genetic disorders", "organSystem": "Congenital, familial and genetic disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 522}]}, {"term": "Multiple endocrine adenomatosis Type II", "organSystem": "Congenital, familial and genetic disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 522}]}, {"term": "Any General disorders and administration site conditions", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 522}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 522}]}, {"term": "Any Infections and infestations", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 522}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 522}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 522}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 522}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 522}]}, {"term": "Any Injury, poisoning and procedural complications", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 522}]}, {"term": "Intervertebral disc injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 522}]}, {"term": "Joint injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 522}]}, {"term": "Tibia fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 522}]}, {"term": "Any Metabolism and nutrition disorders", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 522}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 522}]}, {"term": "Any Neoplasms benign, malignant and unspecified", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 522}]}, {"term": "Lung carcinoma cell type unspecified stage IV", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 522}]}, {"term": "Malignant melanoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 522}]}, {"term": "Metastases to bone", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 522}]}, {"term": "Any Nervous system disorders", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 522}]}, {"term": "Facial palsy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 522}]}, {"term": "Any Renal and urinary disorders", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 522}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 522}]}, {"term": "Any Reproductive system and breast disorders", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 522}]}, {"term": "Hydrometra", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 522}]}], "otherEvents": [{"term": "Any Gastrointestinal disorders", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 57, "numAtRisk": 522}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 528}, {"groupId": "EG001", "numAffected": 57, "numAtRisk": 522}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Site 0490125 was non-compliant with Good Clinical Practice (GCP). Data from the 8 patients at this site were removed from all analyses."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Argentina", "Austria", "Brazil", "Chile", "Colombia", "Denmark", "Estonia", "Finland", "Germany", "Greece", "Hungary", "India", "Ireland", "Lithuania", "Mexico", "Philippines", "Poland", "Russian Federation", "Spain", "Turkey", "United Kingdom", "United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Facial", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Dextromethorphan", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}